COST OF DEVELOPMENT SERVICES AND RESEARCH AND DEVELOPMENT EXPENSES (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands |
Jul. 12, 2024 |
Jul. 10, 2024 |
|---|---|---|
| Broaden [Member] | ||
| Intangiable asset purchase price valued by third party | $ 11,000 | |
| Intangiable asset purchase price valued by third party | $ 10,767 | |
| Share price | $ 30.0 | |
| Common stock issue price | 10.00% | |
| Theracell [Member] | ||
| Intangiable asset purchase price valued by third party | $ 10,324 | |
| Description of ownership percentage | 50% of the outstanding ownership rights and equity interests in Theracell Laboratories IKE (“Theracell IKE”) not currently owned by the Company so that the Company shall own 100% of the outstanding equity interests of Theracell IKE; and | |
| Intangible asset purchase price valued by third party | $ 13,000 | |
| Payment as per agreement description | The aggregate Consideration will be paid by the Company as follows: (i) $400 will be paid to Theracell within 60 days after signing of the Purchase Agreement, (ii) $250 will be paid to Theracell within one year after signing of the Purchase Agreement, and (iii) the remaining amount (less any Debt) will be paid to Theracell in four equal annual payments beginning on December 30, 2025 and ending on December 30, 2028. As of the date of this annual report on Form 10-K, the Company had paid Theracell $243. The Company accounted for the Purchase agreement by recording the difference between the Consideration and Debt as research and development expenses, and the consideration that exceeds the debt was recorded in short term or other long-term liabilities as appropriate. |